Tropolones As Lead-Like Natural Products: The Development of Potent and Selective Histone Deacetylase Inhibitors

被引:88
|
作者
Ononye, Sophia N. [1 ]
VanHeyst, Michael D. [1 ]
Oblak, E. Zachary [1 ]
Zhou, Wangda [1 ]
Ammar, Mohamed [1 ]
Anderson, Amy C. [1 ]
Wright, Dennis L. [1 ]
机构
[1] Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 08期
关键词
Tropolone; HDAC; isozyme-selectivity; thujaplicin; metalloenzyme; T-lymphocyte cancer cell lines; HUMAN HDAC8; THUJAPLICIN; ROUTE; HEART;
D O I
10.1021/ml400158k
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Natural products have long been recognized as a rich source of potent therapeutics but further development is often limited by high structural complexity and high molecular weight. In contrast, at the core of the thujaplicins is a lead-like tropolone scaffold characterized by relatively low molecular weight, ample sites for diversification, and metal-binding functionality poised for targeting a range of metalloenzyme drug targets. Here, we describe the development of this underutilized scaffold for the discovery of tropolone derivatives that function as isozyme-selective inhibitors of the validated anticancer drug target, histone deacetylase (HDAC). Several monosubstituted tropolones display remarkable levels of selectivity for HDAC2 and potently inhibit the growth of T-cell lymphocyte cell lines. The tropolones represent a new chemotype of isozyme-selective HDAC inhibitors.
引用
收藏
页码:757 / 761
页数:5
相关论文
共 50 条
  • [21] Histone deacetylase inhibitors as potent modulators of cellular contacts
    Vinken, Mathieu
    Peggy, Papeleu
    Vera, Rogiers
    Tamara, Vanhaecke
    CURRENT DRUG TARGETS, 2006, 7 (06) : 773 - 787
  • [22] New aryldithiolethione derivatives as potent histone deacetylase inhibitors
    Tazzari, Valerio
    Cappelletti, Graziella
    Casagrande, Manolo
    Perrino, Elena
    Renzi, Luigi
    Del Soldato, Piero
    Sparatore, Anna
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (12) : 4187 - 4194
  • [23] Selective Histone Deacetylase Inhibitors with Anticancer Activity
    Ma, Nan
    Luo, Ying
    Wang, Ying
    Liao, Chenzhong
    Ye, Wen-Cai
    Jiang, Sheng
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (04) : 415 - 426
  • [24] Isoform-selective histone deacetylase inhibitors
    Bieliauskas, Anton V.
    Pflum, Mary Kay H.
    CHEMICAL SOCIETY REVIEWS, 2008, 37 (07) : 1402 - 1413
  • [25] Strategies To Design Selective Histone Deacetylase Inhibitors
    Melesina, Jelena
    Simoben, Conrad V.
    Praetorius, Lucas
    Bulbul, Emre F.
    Robaa, Dina
    Sippl, Wolfgang
    CHEMMEDCHEM, 2021, 16 (09) : 1336 - 1359
  • [26] Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties
    Sun, Ping
    Wang, Jing
    Khan, Khadija S.
    Yang, Weiqin
    Ng, Billy Wai-Lung
    Ilment, Nikita
    Zessin, Matthes
    Buelbuel, Emre F.
    Robaa, Dina
    Erdmann, Frank
    Schmidt, Matthias
    Romier, Christophe
    Schutkowski, Mike
    Cheng, Alfred Sze-Lok
    Sippl, Wolfgang
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16313 - 16337
  • [27] Isoform-selective histone deacetylase inhibitors
    Itoh, Yukihiro
    Suzuki, Takayoshi
    Miyata, Naoki
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (06) : 529 - 544
  • [28] Largazole analogs as selective histone deacetylase inhibitors
    Al-Hamashi, Ayad
    Almaliti, Jehad
    Farrell, Robert
    Tillekeratne, Viranga
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [29] Discovery of histone deacetylase 8 selective inhibitors
    Tang, Weiping
    Luo, Tuoping
    Greenberg, Edward F.
    Bradner, James E.
    Schreiber, Stuart L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) : 2601 - 2605
  • [30] Discovery and development of histone deacetylase inhibitors
    Yoshida, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U162 - U162